Search

Search Constraints

You searched for: Author/Creator Such, E.

Search Results

1. 206 IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT (HSCT). GESMD STUDY. Issue 1 (April 2015)

2. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS. Issue 1 (April 2015)

3. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Issue 1 (April 2015)

5. 83 PERCENTAGE OF BLASTS IN CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE-1 HAS NO IMPACT ON OVERALL SURVIVAL IN A SERIES OF PATIENTS FROM THE SPANISH REGISTRY OF MDS. (April 2015)

6. A Single Next-Generation Sequencing (NGS) Assay for the Detection of Point Mutations and Large Chromosomal Abnormalities in MDS Patients. (April 2017)

7. Azacitidine Improves Outcome in High Risk MDS Patients with Chromosome 7 Abnormalities: Retrospective Comparison of GESMD and GFM Registries. (April 2017)

8. Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation. (April 2017)

9. Impact of DNMT3A and IDH1/IDH2 Mutations on Treatment Response with Azacitidine in Myeloid Neoplasms. (April 2017)

10. Interpretation of NGS Results for Clinical Practice in Myelodysplastic Syndromes. (April 2017)